Young Sil Eom

Young Sil Eom

Auto-generated profile, based on publicly available information

Young Sil Eom

Division of Endocrinology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
YEYoung Sil Eom
Young Sil Eom
JWJessica R. Wilson
Jessica R. Wilson
VBVictor J. Bernet
Victor J. Bernet
Thyroid disorders and diabetes mellitus often coexist and are closely related. Several studies have shown a higher prevalence of thyroid disorders in patients with diabetes mellitus and vice versa. Thyroid hormone affects glucose homeostasis by impacting pancreatic β-cell development and glucose metabolism through several organs such as the liver, gastrointestinal tract, pancreas, adipose tissue, skeletal muscles, and the central nervous system. The present review discusses the effect of thyroid hormone on glucose homeostasis. We also review the relationship between thyroid disease and diabetes mellitus: type 1, type 2, and gestational diabetes, as well as guidelines for screening thyroid function with each disorder. Finally, we provide an overview of the effects of antidiabetic drugs on thyroid hormone and thyroid disorders.

20 December 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YEYoung Sil Eom
Young Sil Eom
AGA-Ryeong Gwon
A-Ryeong Gwon
KKKyung Min Kwak
Kyung Min Kwak
JKJu-Young Kim
Ju-Young Kim
SYSeung Hee Yu
Seung Hee Yu
BKByung-Joon Kim
Byung-Joon Kim
Long-term use of thiazolidinediones (TZDs) is associated with bone loss and an increased risk of fracture in patients with type 2 diabetes (T2DM). Incretin-based drugs (glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors) have several benefits in many systems in addition to glycemic control. In a previous study, we reported that exendin-4 might increase bone mineral density (BMD) by decreasing the expression of SOST/sclerostin in osteocytes in a T2DM animal model. In this study, we investigated the effects of a DPP-4 inhibitor on TZD-induced bone loss in a T2DM animal model. We randomly divided 12-week-old male Zucker Diabetic Fatty (ZDF) rats into four groups; control, vildagliptin, pioglitazone, and vildagliptin and pioglitazone combination. Animals in each group received the respective treatments for 5 weeks. We performed an intraperitoneal glucose tolerance test (IPGTT) before and after treatment. BMD and the trabecular micro-architecture were measured by DEXA and micro CT, respectively, at the end of the treatment. The circulating levels of active GLP-1, bone turnover markers, and sclerostin were assayed. Vildagliptin treatment significantly increased BMD and trabecular bone volume. The combination therapy restored BMD, trabecular bone volume, and trabecular bone thickness that were decreased by pioglitazone. The levels of the bone formation marker, osteocalcin, decreased and that of the bone resorption marker, tartrate-resistant acid phosphatase (TRAP) 5b increased in the pioglitazone group. These biomarkers were ameliorated and the pioglitazone-induced increase in sclerostin level was lowered to control values by the addition of vildagliptin. In conclusion, our results indicate that orally administered vildagliptin demonstrated a protective effect on pioglitazone-induced bone loss in a type 2 diabetic rat model.

31 January 2021 in Diabetes & Metabolism Journal
Verified
Journal Article
Open access
PDF file
YEYoung Sil Eom
Young Sil Eom
AGA-Ryeong Gwon
A-Ryeong Gwon
KKKyung Min Kwak
Kyung Min Kwak
JYJin-Young Youn
Jin-Young Youn
HPHeekyoung Park
Heekyoung Park
BKByung-Joon Kim
Byung-Joon Kim
Eom YS, et al. Diabetes Metab J. 2020 Jan;44:e4. https://doi.org/10.4093/dmj.2019.0160

8 November 2011 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
HYHyon‐Seung Yi
Hyon‐Seung Yi
YEYoung Sil Eom
Young Sil Eom
IPIe Byung Park
Ie Byung Park
SLSangho Lee
Sangho Lee
SHSuntaek Hong
Suntaek Hong
SLSihoon Lee
Sihoon Lee

1 April 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
DSDongseong Shin
Dongseong Shin
YEYoung Sil Eom
Young Sil Eom
SCSuk Chon
Suk Chon
BKByung-Joon Kim
Byung-Joon Kim
KYKyung-Sang Yu
Kyung-Sang Yu
Dae Ho LeeDae Ho Lee
Dae Ho Lee
Background and objective: The effects of age and related factors on insulin sensitivity have not been definitively evaluated in East Asian populations. We proposed a reference range for the glucose disposal rate (M-value) on hyperinsulinemic-euglycemic study and its association with other parameters. Methods: Healthy, non-diabetic young (n=10) and elderly (n=13) male subjects with normal body mass index were eligible for this study. Subjects who passed the oral glucose tolerance test (OGTT) underwent hyperinsulinemic-euglycemic clamp with high-dose (80 mU/m2·min) insulin infusion. Results: M-values were normalized to body weight (MBW) and fat-free mass (MFFM). Neither M-value was significantly different between age groups (P=0.458 and P=0.900, respectively). An inverse correlation was observed between MFFM and baseline insulin (r=−0.418; P=0.047), baseline C-peptide (r=−0.426; P=0.043) and OGTT 2-hour glucose (r=−0.452; P=0.030). Regarding correlations with other insulin sensitivity indices, M-values were positively associated with the Matsuda index but not with homeostasis model assessment of insulin resistance. Conclusion: Our results suggest that age is not a critical determinant of insulin sensitivity, while fasting insulin and C-peptide levels, OGTT 2-hour glucose level, and Matsuda index are predictable markers of insulin sensitivity in healthy Koreans.

22 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
POPyung Chun Oh
Pyung Chun Oh
YEYoung Sil Eom
Young Sil Eom
JMJeonggeun Moon
Jeonggeun Moon
HJHo-Jun Jang
Ho-Jun Jang
TKTae-Hoon Kim
Tae-Hoon Kim
WKWoong Chol Kang
Woong Chol Kang
Elevated serum transaminase or alkaline phosphatase (ALP) has been proposed as a novel prognosticator for ST-segment elevation myocardial infarction (STEMI). We evaluated the combined prognostic impact of elevated serum transaminases and ALP on admission in STEMI patients who underwent primary percutaneous coronary intervention (PCI). A total of 1176 patients with STEMI undergoing primary PCI were retrospectively enrolled from the INTERSTELLAR registry. Hypoxic liver injury (HLI) was defined as serum transaminase > twice the upper limit of normal. The cut-off value of high ALP was set at the median level (73 IU/L). Patients were divided into four groups according to their serum transaminase and ALP levels. The primary endpoint was major adverse cardiac or cerebrovascular events (MACCE), defined as the composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, and ischemia-driven revascularization. Median follow-up duration was 25 months (interquartile range, 10–39 months). The rate of MACCE was highest in patients with HLI (+) and high ALP (25.9%), compared to those in the other groups (8.2% in HLI [-] and low ALP, 11.8% in HLI [-] and high ALP, and 15.0% in HLI [+] and low ALP). Each of HLI or high ALP was an independent predictor for MACCE (HR 1.807, 95% CI 1.191–2.741; HR 1.721, 95% CI 1.179–2.512, respectively). Combined HLI and high ALP was associated with the worst prognosis (HR 3.145, 95% CI 1.794–5.514). Combined HLI and high ALP on admission is associated with poor clinical outcomes in patients with STEMI who have undergone primary PCI.